Penn Capital Management Company LLC Sells 34,265 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Penn Capital Management Company LLC lessened its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 10.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 307,991 shares of the company’s stock after selling 34,265 shares during the quarter. Mirum Pharmaceuticals comprises about 1.7% of Penn Capital Management Company LLC’s investment portfolio, making the stock its 4th biggest position. Penn Capital Management Company LLC owned about 0.60% of Mirum Pharmaceuticals worth $22,630,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MIRM. Comerica Bank boosted its holdings in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC increased its stake in shares of Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Mirum Pharmaceuticals by 7.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the last quarter. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals during the 1st quarter valued at approximately $217,000. Finally, Empowered Funds LLC boosted its stake in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the period.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum announced completion of enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat), keeping the program on schedule for topline data in Q4 2026 — a material catalyst that could drive upside if efficacy/safety readouts are strong. Read More.
• Neutral Sentiment: Analyst momentum and institutional holdings remain supportive: several firms have raised price targets recently and large institutional investors (Janus Henderson, State Street, Wellington, Arrowstreet) hold meaningful positions — this underpins valuation but doesn’t eliminate binary clinical risk. Read More.
• Negative Sentiment: Clustered insider selling: CEO Christopher Peetz sold ~40,985 shares (~$3.77M), COO Peter Radovich ~16,515 shares (~$1.52M), CFO Eric Bjerkholt and other senior insiders sold additional blocks on March 16 — collectively millions of dollars at ~ $91.98/share and double‑digit percentage reductions in their holdings. Large, simultaneous insider sales can be perceived as profit‑taking or reduced conviction and may pressure the stock near term. SEC filings and trade reports: Read More. Read More. Read More.

Mirum Pharmaceuticals Stock Up 4.2%

MIRM opened at $96.55 on Wednesday. The company has a market capitalization of $5.83 billion, a P/E ratio of -201.14 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The firm’s fifty day moving average price is $96.13 and its two-hundred day moving average price is $81.00. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The business had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The company’s quarterly revenue was up 49.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.00 EPS. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analysts Set New Price Targets

MIRM has been the topic of several recent analyst reports. Evercore set a $126.00 price target on Mirum Pharmaceuticals in a research report on Wednesday, March 4th. Wall Street Zen cut Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 28th. Raymond James Financial restated a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Stifel Nicolaus boosted their target price on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Morgan Stanley upped their target price on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Insiders Place Their Bets

In related news, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $17,872,541.82. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jolanda Howe sold 4,732 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $435,249.36. Following the transaction, the senior vice president owned 8,429 shares of the company’s stock, valued at approximately $775,299.42. This represents a 35.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 121,942 shares of company stock valued at $11,416,645 over the last 90 days. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.